FRSW117

DRUG3 trials

Sponsors

Jiangsu Gensciences lnc., Hangzhou Gensciences Biopharmaceutical Co., Ltd.

Conditions

Severe Hemophilia A

Phase 1

A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

CompletedNCT04864743

Jiangsu Gensciences lnc.Severe Hemophilia A

Start: 2021-06-22End: 2021-10-17Updated: 2023-09-08

Phase 2

A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

CompletedNCT05265286

Jiangsu Gensciences lnc.Severe Hemophilia A

Start: 2022-04-14End: 2022-08-21Updated: 2023-05-15

Phase 3

Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

CompletedNCT06142552

Hangzhou Gensciences Biopharmaceutical Co., Ltd.Severe Hemophilia A

Start: 2023-12-27End: 2025-10-19Updated: 2026-09-09

Related Papers

Pharmacokinetics, Safety and Preliminary Efficacy of Multiple Doses of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW117) in Previously Treated Adult and Adolescent Subjects with Severe Hemophilia a: Results from an Open-Label, Multicenter, Phase 2 Study

Blood2023-11-02

P1617: A PHASE 1 STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF A PEGYLATED-RECOMBINANT HUMAN COAGULATION FACTOR VIII-FC FUSION PROTEIN WITH HALF-LIFE IN PATIENTS WITH SEVERE HEMOPHILIA A

HemaSphere2023-08-011 citations